an anecdotal study of low dose naltrexone · therapy in relapse remitting ms. citations goodin,...
TRANSCRIPT
An Anecdotal Studyof Low Dose Naltrexone
Skip Lenz Pharm.D. F.A.S.C.P.with Research Assistants
Shanna Chambliss Pharm.D. (Candidate) University of FloridaVinay Patel Pharm.D. (Candidate) University of Florida
Bandar Saleh Pharm.D. (Candidate) P.B.A. School of PharmacyJeremy Thomas Pharm.D. (Candidate) University of Florida
Hew Fong Pharm.D. (Candidate) University of FloridaFelicia Fong Kong Pharm.D. (Candidate) University of Florida
Skip’s PharmacyBoca Raton, Fl.
Demographics
• Number of patients surveyed: 242 (p=v0.5)• Number of patients with diagnosis of MS: 207 (as reported by patients)
• Chronic progressive: 8 (4%)• Primary progressive: 13 (6%)• Secondary progressive: 35 (17%)• Relapse remitting: 79 (38%)• Unknown: 72 (35%)
• Number of Patients with diagnosis other then MS: 35 (as reported bypatients)• Cancer: 13• Fibromyalgia: 5• Neuropathy: 3• Prophylaxis: 3• Other: 11
• Time Period Represented: 12/01/00 - 06/30/05
Questionnaire1. What is the reason (your diagnosis) for taking LDN
2. How long have you had this condition/disease
3. (if the diagnosis is Multiple Sclerosis) -Is the Condition type progressive or relapse/remitting? Or other
4. (if relapse remitting MS)When was your last exacerbation?
5. How would you rate your symptoms after starting LDN vs. beforeLDN
a) Worsened b) No Change c) Improved
6. How long did it take for you to see a change in your symptomssince you started LDN?
Types of MS Reported by Patients
Primary ProgressiveSecondary ProgressiveRelapse RemittingChronic ProgressiveUnknown by Patient
Overall Results After TakingLDN
ImprovedNo ChangeWorsened
Relapse Remitting Results
ImprovedNo ChangeWorsenedMixed
3(4%)
1(1%)
Unknown by Patient Results
ImprovedNo ChangeWorsened
Primary Progressive Results
No ChangeImproved
Secondary Progressive Results
ImprovedNo ChangeWorsened
Chronic Progressive Results
ImprovedNo ChangeMixed
Days To Results Versus Number ofYears with Diagnosis
% Improvement Based onType of Drug Therapy
% Improvement Based on type of DrugTherapy in Relapse Remitting MS
Citations
www.avonex.comwww.rebif.comwww.betaseron.comwww.popaxone.comwww.novantrone.com
Goodin, D.S. "Disease ModifyingTherapy in Multiple Sclerosis”Report of the Therapeutic andTechnology AssessmentSubcommittee of the AmericanAcademy of Neurology and the MSCouncil for Clinical PracticeGuidelines. Neurology #58 Jan2002 pg. 169-178
Goodin, D.S. "The Use of Mitoxantrone(novantrone) for the treatment ofMultiple Sclerosis" Report of theTherapeutic and TechnologyAssessment Subcommittee of theAmerican Academy of Neurology.Neurology #61 Nov. 2003 pg. 1332-1338